Meriwether Wealth & Planning LLC Makes New Investment in Sanofi (NASDAQ:SNY)

Meriwether Wealth & Planning LLC acquired a new position in Sanofi (NASDAQ:SNY) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,172 shares of the company’s stock, valued at approximately $587,000.

Other large investors have also recently bought and sold shares of the company. Synergy Asset Management LLC purchased a new position in Sanofi in the fourth quarter worth $25,000. McClarren Financial Advisors Inc. increased its position in shares of Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after buying an additional 543 shares in the last quarter. Sunbelt Securities Inc. increased its position in shares of Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after buying an additional 313 shares in the last quarter. Sierra Ocean LLC purchased a new position in shares of Sanofi in the fourth quarter valued at $44,000. Finally, Versant Capital Management Inc purchased a new position in shares of Sanofi in the fourth quarter valued at $54,000. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Trading Down 0.3 %

Sanofi stock opened at $59.25 on Monday. The stock has a market cap of $150.37 billion, a PE ratio of 23.80, a P/E/G ratio of 1.01 and a beta of 0.58. The stock has a 50-day moving average price of $52.65 and a 200 day moving average price of $52.73. Sanofi has a 52 week low of $45.22 and a 52 week high of $59.72. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Equities research analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on SNY. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.